Abrdn Life Sciences Investors Schedule 13D activist filings

Saba Capital Management, L.P. and affiliates reported a reduction in their beneficial ownership of abrdn Life Sciences Investors to 4.95% through open market sales.

Saba Capital Management, L.P. and affiliates have reduced their beneficial ownership in abrdn Life Sciences Investors, selling shares between January and February 2026.

Saba Capital Management, L.P. has reduced its beneficial ownership in abrdn Life Sciences Investors to 6.77% through open market sales.

Saba Capital Management, L.P. and its affiliates have amended their beneficial ownership in abrdn Life Sciences Investors to 7.88% of common shares, reporting recent open market transactions.

Saba Capital Management, L.P. has filed an amended Schedule 13D, disclosing a reduction in its beneficial ownership of abrdn Life Sciences Investors to 8.96% through recent open market sales.

Saba Capital Management, L.P. has filed an Amendment No. 7 to its Schedule 13D, reporting a 10.33% beneficial ownership in abrdn Life Sciences Investors after recent share sales.

Saba Capital Management, L.P. and its affiliates filed an Amendment No. 6 to their Schedule 13D, disclosing a continued beneficial ownership of 11.36% in abrdn Life Sciences Investors and detailing recent share sales.